Use of menopausal hormone therapy and risk of ductal and lobular breast cancer among women 55-74 years of age

Breast Cancer Research and Treatment

Volumn 145, Issue 2, 2014, Pages 481-489

  Li, Christopher I ^a   Daling, Janet R ^a   Haugen, Kara L ^a   Tang, Mei Tzu Chen ^a   Porter, Peggy L ^a   Malone, Kathleen E ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Breast cancer; Ductal carcinoma; Estrogen; Lobular carcinoma; Menopausal hormone therapy; Progesterone

Indexed keywords

ESTROGEN; GESTAGEN; ESTROGEN RECEPTOR;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BREAST CARCINOMA; CANCER CLASSIFICATION; CANCER PREVENTION; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; DISEASE ASSOCIATION; EVIDENCE BASED MEDICINE; FEMALE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSE; MIDDLE AGED; PAGET NIPPLE DISEASE; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; TREATMENT DURATION; TUMOR VOLUME; ADVERSE EFFECTS; BREAST TUMOR; CASE CONTROL STUDY; CHEMICALLY INDUCED; ESTROGEN THERAPY; HORMONE SUBSTITUTION; LUNG CARCINOMA; METABOLISM; PATHOLOGY; RISK ASSESSMENT;

AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CASE-CONTROL STUDIES; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MENOPAUSE; MIDDLE AGED; PROGESTINS; RECEPTORS, ESTROGEN; RISK ASSESSMENT;

EID: 84901693392     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-2960-4     Document Type: Article

References (24)

1. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, Rodabough RJ, Gilligan MA, Cyr MG, Thomson CA, Khandekar J, Petrovitch H, McTiernan A (2003) Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 289:3243-3253 (Pubitemid 37430077)
2. Li CI, Daling JR (2007) Changes in breast cancer incidence rates in the United States by histologic subtype and race/ethnicity, 1995 to 2004. Cancer Epidemiol Biomarkers Prev 16:2773-2780 (Pubitemid 351196336)
3. Calle EE, Feigelson HS, Hildebrand JS, Teras LR, Thun MJ, Rodriguez C (2009) Postmenopausal hormone use and breast cancer associations differ by hormone regimen and histologic subtype. Cancer 115:936-945
4. Chen CL, Weiss NS, Newcomb P, Barlow W, White E (2002) Hormone replacement therapy in relation to breast cancer. JAMA 287:734-741 (Pubitemid 34250459)
5. Daling JR, Malone KE, Doody DR, Voigt LF, Bernstein L, Coates RJ, Marchbanks PA, Norman SA, Weiss LK, Ursin G, Berlin JA, Burkman RT, Deapen D, Folger SG, McDonald JA, Simon MS, Strom BL, Wingo PA, Spirtas R (2002) Relation of regimens of combined hormone replacement therapy to lobular, ductal, and other histologic types of breast carcinoma. Cancer 95:2455-2464 (Pubitemid 35424029)
6. Flesch-Janys D, Slanger T, Mutschelknauss E, Kropp S, Obi N, Vettorazzi E, Braendle W, Bastert G, Hentschel S, Berger J, Chang-Claude J (2008) Risk of different histological types of postmenopausal breast cancer by type and regimen of menopausal hormone therapy. Int J Cancer 123:933-941 (Pubitemid 352032424)
7. Fournier A, Fabre A, Mesrine S, Boutron-Ruault MC, Berrino F, Clavel-Chapelon F (2008) Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer. J Clin Oncol 26:1260-1268
8. Garcia-Closas M, Brinton LA, Lissowska J, Chatterjee N, Peplonska B, Anderson WF, Szeszenia-Dabrowska N, Bardin-Mikolajczak A, Zatonski W, Blair A, Kalaylioglu Z, Rymkiewicz G, Mazepa-Sikora D, Kordek R, Lukaszek S, Sherman ME (2006) Established breast cancer risk factors by clinically important tumour characteristics. Br J Cancer 95:123-129 (Pubitemid 43980566)
9. Kotsopoulos J, Chen WY, Gates MA, Tworoger SS, Hankinson SE, Rosner BA (2010) Risk factors for ductal and lobular breast cancer: results from the nurses' health study. Breast Cancer Res 12:R106
10. Li CI, Malone KE, Porter PL, Lawton TJ, Voigt LF, Cushing-Haugen KL, Lin MG, Yuan X, Daling JR (2008) Relationship between menopausal hormone therapy and risk of ductal, lobular, and ductal-lobular breast carcinomas. Cancer Epidemiol Biomarkers Prev 17:43-50 (Pubitemid 351196272)
11. Li CI, Malone KE, Porter PL, Weiss NS, Tang MT, Cushing-Haugen KL, Daling JR (2003) Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA 289:3254-3263 (Pubitemid 37430078)
12. Li CI, Weiss NS, Stanford JL, Daling JR (2000) Hormone replacement therapy in relation to risk of lobular and ductal breast carcinoma in middle-aged women. Cancer 88:2570-2577 (Pubitemid 30331965)
13. Newcomb PA, Titus-Ernstoff L, Egan KM, Trentham-Dietz A, Baron JA, Storer BE, Willett WC, Stampfer MJ (2002) Postmenopausal estrogen and progestin use in relation to breast cancer risk. Cancer Epidemiol Biomarkers Prev 11:593-600 (Pubitemid 34760816)
14. Newcomer LM, Newcomb PA, Potter JD, Yasui Y, Trentham-Dietz A, Storer BE, Longnecker MP, Baron JA, Daling JR (2003) Postmenopausal hormone therapy and risk of breast cancer by histologic type (United States). Cancer Causes Control 14:225-233 (Pubitemid 36649145)
15. Reeves GK, Beral V, Green J, Gathani T, Bull D (2006) Hormonal therapy for menopause and breast-cancer risk by histological type: A cohort study and meta-analysis. Lancet Oncol 7:910-918 (Pubitemid 44615945)
16. Rosenberg LU, Magnusson C, Lindstrom E, Wedren S, Hall P, Dickman PW (2006) Menopausal hormone therapy and other breast cancer risk factors in relation to the risk of different histological subtypes of breast cancer: A case-control study. Breast Cancer Res 8:R11 (Pubitemid 44644828)
17. Brinton LA, Richesson D, Leitzmann MF, Gierach GL, Schatzkin A, Mouw T, Hollenbeck AR, Lacey JV Jr (2008) Menopausal hormone therapy and breast cancer risk in the NIH-AARP Diet and Health Study Cohort. Cancer Epidemiol Biomarkers Prev 17:3150-3160
18. Lee S, Kolonel L, Wilkens L, Wan P, Henderson B, Pike M (2006) Postmenopausal hormone therapy and breast cancer risk: the multiethnic cohort. Int J Cancer 118:1285-1291 (Pubitemid 43185619)
19. Ursin G, Tseng CC, Paganini-Hill A, Enger S, Wan PC, Formenti S, Pike MC, Ross RK (2002) Does menopausal hormone replacement therapy interact with known factors to increase risk of breast cancer? J Clin Oncol 20:699-706 (Pubitemid 34111377)
20. Wei F, Miglioretti DL, Connelly MT, Andrade SE, Newton KM, Hartsfield CL, Chan KA, Buist DS (2005) Changes in women's use of hormones after the Women's Health Initiative estrogen and progestin trial by race, education, and income. J Natl Cancer Inst Monogr 35:106-112
21. Waksberg J (1978) Sampling methods for random digit dialing. J Am Stat Assoc 73:40
22. Voigt LF, Davis S, Heuser L (1992) Random digit dialing: the potential effect on sample characteristics of the conversion of nonresidential telephone numbers. Am J Epidemiol 136:1393-1399 (Pubitemid 23046424)
23. Begg CB, Gray R (1984) Calculation of polychotomous logistic regression parameters using individualized regressions. Biometrika 71:11-18
24. Slanger TE, Chang-Claude JC, Obi N, Kropp S, Berger J, Vettorazzi E, Braendle W, Bastert G, Hentschel S, Flesch-Janys D (2009) Menopausal hormone therapy and risk of clinical breast cancer subtypes. Cancer Epidemiol Biomarkers Prev 18:1188-1196